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Abstract
Background: Using gene expression profiling, we previously identified CDC25B to be significantly
highly expressed in hepatocellular carcinoma (HCC) compared to non-tumor liver. CDC25B is a
cell cycle-activating phosphatase that positively regulates the activity of cyclin-dependent kinases,
and is over-expressed in a variety of human malignancies. In this study, we validated the over-
expression of CDC25B in HCC, and further investigated its potential as a therapeutic target for
the management of HCC.
Results: Quantitative real-time polymerase chain reaction and immunohistochemical staining of
patient samples confirmed the significant over-expression of CDC25B in HCC compared to non-
tumor liver samples (P < 0.001). Thus, intefering with the expression and activity of CDC25B may
be a potential way to intervene with HCC progression. We used RNA interference to study the
biological effects of silencing CDC25B expression in HCC cell lines (Hep3B and Hep40), in order
to validate its potential as a therapeutic target. Using small oligo siRNAs targeting the coding region
of CDC25B, we effectively suppressed CDC25B expression by up to 90%. This was associatetd
with significant reductions in cell growth rate, cell migration and invasion through the matrigel
membrane, and caused significant cell cycle delay at the G2 phase. Finally, suppression of CDC25B
significantly slowed the growth of Hep40 xenografts in nude mice.
Conclusion: Our data provide evidence that the inhibition of CDC25B expression and activity
lead to suppression of tumor cell growth and motility, and may therefore be a feasible approach in
the clinical management of HCC.
Background
Hepatocellular carcinoma (HCC) is the primary adult
malignancy of the liver, and is the fifth most frequent can-
cer in the world [1]. It causes significant mortality, espe-
cially in countries where there is a high prevalence of
chronic hepatitis B virus and hepatitis C virus infection
[2]. One of the reasons for this high mortality is that the
tumor usually presents at a stage when curative surgery is
no longer feasible because of intrahepatic or extrahepatic
metastases. Therefore, more effective therapies need to be
developed to treat HCC patients who are not surgical can-
didates.
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All cancers share the common feature of a disordered cell
cycle that is characterized by rapid and uncontrolled cell
growth. Thus, targeting the molecules that regulate the cell
cycle has become a major thrust in the development of
anticancer therapeutics [3]. CDC25 phosphatases, as acti-
vators of the Cdk/cyclins, play critical roles in the regula-
tion of the eukaryotic cell cycle. Because of their over-
expression and correlation with poor prognosis in many
diverse cancers, CDC25 phosphatases are attractive targets
for anticancer drug development. The three human
CDC25 isoforms (CDC25A, CDC25B, and CDC25C) are
responsible for dephosphorylating Cdk/cyclins on
pThr14 and/or pTyr15 residues. This dephosphorylation
triggers the final activation of Cdk/cyclin activity during
normal cell cycle progression [4,5]. CDC25A controls
both the G1-to-S and G2-to-M transitions, whereas
CDC25B and CDC25C are regulators of the G2-to-M tran-
sition. The activity of CDC25B is highly regulated by
phosphorylation via several protein kinases (e. g. CK1,
PKB/Akt, CDK/cyclin, p38, MAPKAP kinase 2, pEg3 and
aurora A), which in turn regulate CDC25B activity, stabil-
ity and/or subcellular localization [6-14]. Thus, at the
same stage of the cell cycle, a large diversity of phosphor-
ylated CDC25B molecules with different properties and
functions may be generated via the activity of several inde-
pendent kinases.
CDC25A and CDC25B, being oncogenes, are over-
expressed in many different primary human cancers, such
as head and neck cancer, poorly differentiated non-small
cell lung cancer, advanced stage gastric cancer, non-Hodg-
kin's lymphomas, colon cancer, esophagus cancer, breast
cancer, and ovarian cancer. [15-22]. Over-expressions of
CDC25A and CDC25B are often associated with malig-
nant features such as higher grade and more agrressive
tumors, and poorer prognosis [23]. Xu et al recently
reported the over-expression of CDC25A mRNA and pro-
tein in HCV-associated HCC tumors compared to paired
non-tumor liver tissues. The over-expression of CDC25A
was also associated with aggressive cancer phenotypes
including portal vein invasion and dedifferentiated histol-
ogy. In contrast, CDC25B was not over-expressed in HCV-
associated HCC tumors, and was not associated with any
clinicopathological parameters.
Our group previously studied the gene expression profiles
in over 200 liver tissue samples [24], and identified
CDC25B as one of most significantly over-expressed genes
in HCC compared to non-tumor liver. We first validated
the over-expression of CDC25B in HCC, at both the RNA
and protein levels. Next, we used specific small inhibitory
RNA oligos against CDC25B to study the biological effects
of CDC25B suppression in HCC cell lines, especially in
regard to cell proliferation, invasion, migration, and cell
cycle. Our results suggest that CDC25B may be a potential
diagnostic marker, as well as a therapeutic target for HCC.
Results
CDC25B is significantly overexpressed in hepatocellular 
carcinoma compared to non-tumor liver
In an earlier gene expression study of hepatocellular carci-
noma, CDC25B was upregulated in tumor compared to
non-tumor samples. We used quantitative real-time PCR
assays to validate the observed upregulation of CDC25B
in hepatocellular carcinoma using 24 pairs of HCC tissues
and adjacent non-tumor tissues. CDC25B was found to be
expressed at significantly higher levels in HCC (median of
0.443) compared to adjacent non-tumors (median of
0.149) (P < 0.001) (Fig. 1A). Further statistical analyses
showed no significant correlations between CDC25B
transcript over-expression and clinicopathological fea-
tures of the specimens.
Immunohistochemistry of liver tissue arrays further con-
firmed the over-expression of CDC25B protein in HCC
tissues compared to non-tumor liver tissues (P < 0.001)
(Table 1, Fig. 1B). Whereas only 1/42 (2.4%) non-tumor
tissues showed greater than intermediate signal, 142/248
(57.3%) of HCC tissues showed intermediate or strong
signal. Staining of CDC25B was observed in the cyto-
plasm. The lack of detailed clinical information from
these archived pathology specimens precluded further
analyses of associations between CDC25B protein over-
expression and other clinicopathological features.
siRNA effectively suppresses CDC25B expression in Hep3B 
and Hep40 cells
To validate the potential of CDC25B as a therapeutic tar-
get for HCC, our approach was to use siRNA oligos to
deplete CDC25B expression in HCC cells, and to study the
biological effects of this suppression. Three CDC25B-spe-
cific siRNA (siRNA1-CDC25B, siRNA2-CDC25B, and
siRNA3-CDC25B) and negative control siRNA-N (all at 50
nM) were transfected into Hep3B and Hep40 cells (2 tum-
origenic cell lines that over-express CDC25B based on
Western blot results). Western blotting confirmed sup-
pression of CDC25B expression in CDC25B siRNA trans-
fected cells, with greatest suppression by siRNA2-
CDC25B. Cells transfected with siRNA-N or RNAiMAX
alone had no effects on CDC25B expression (data not
shown). We therefore chose to use siRNA2-CDC25B for
all subsequent experiments.
Transfection with siRNA2-CDC25B caused a dose-
dependent decrease in CDC25B mRNA levels 48 hours
post-transfection (Fig. 2), with greatest suppressions at 50
nM and 100 nM concentrations in both Hep3B (Fig. 2A)
and Hep40 cells (Fig. 2B). At 50 nM siRNA2-CDC25B,
mRNA levels were suppressed by up to 86% in Hep3B cellMolecular Cancer 2008, 7:19 http://www.molecular-cancer.com/content/7/1/19
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lines and 90% in Hep40 cell line by siRNA2-CDC25B.
Since 100 nM did not cause greater suppression than 50
nM, we used 50 nM siRNA2-CDC25B for all subsequent
experiments.
Silencing of CDC25B inhibits proliferation, invasion and 
migration in Hep3B and Hep40 cells
We next studied the effects of CDC25B suppression on the
growth and invasive properties of HCC cell lines. Hep3B
and Hep40 cells were transfected with siRNA-N or
siRNA2-CDC25B, and cell growth was assessed daily over
4 days. Both cell lines transfected with siRNA2-CDC25B
showed significantly slower growth rates than untrans-
fected or siRNA-N transfected cells (P < 0.01 at 72 hours
and 96 hours; Fig. 3A). This suggests that CDC25B medi-
ates cell proliferation in HCC cells, and that its suppres-
sion led to growth inhibition (Fig. 3A).
Additionally, Hep3B and Hep40 cells transfected with
siRNA2-CDC25B showed significantly reduced ability to
migrate across non-Matrigel coated control membranes (P
< 0.01; Fig. 3B) and to invade through Matrigel coated
membranes (P < 0.01; Fig. 3B). After siRNA2-CDC25B
transfection, migration of Hep3B and Hep40 cells were
decreased by 4 and 2-folds respectively, and invasion were
decreased by 4 and 5-folds respectively, relative to cells
transfected with control siRNA-N. These findings indicate
that silencing of CDC25B has significant inhibitory effects
on cell invasion and migration.
Silencing of CDC25B delays G2/M transition in Hep3B and 
Hep40 cells
To monitor the effect of CDC25B siRNA targeting on the
cell cycle, we analyzed the DNA content of siRNA-trans-
fected Hep3B and Hep40 cells by FACS at 48 hours after
transfection. After siRNA2-CDC25B transfection, the per-
centage of cells in G2 or M phase was increased by 1.6 and
1.9 folds in Hep3B or Hep40 cells respectively (Fig. 4).
Cells transfected with siRNA-N showed no changes in cell
cycle distribution. The results demonstrated that RNAi-
mediated reduction of CDC25B level leads to a delay in
the G2/M transition.
CDC25B is over-expressed in hepatocellular carcinoma  compared to non-tumor liver Figure 1
CDC25B is over-expressed in hepatocellular carci-
noma compared to non-tumor liver. A) Significant over-
expression of CDC25B transcript in hepatocellular carci-
noma tumor compared to adjacent non-tumor liver in 24 
pairs of tissue specimens (P < 0.001). The amount of 
CDC25B was normalized with 18s rRNA to control for RNA 
amount variation. B) Representative immunostaining of 
CDC25B in hepatocellular carcinoma tissue and adjacent 
non-tumor liver tissue. Photos were taken at ×20 magnifica-
tion.
Table 1: CDC25B protein expression in human HCC and non-
tumor liver tissuesa
CDC25B protein expression score HCC Non-tumor
(n = 248) (n = 42)
0 (negative) 26 (10.5%) 24 (57.1%)
1 (weak signal) 80 (32.3%) 17 (40.4%)
2 (intermediate signal) 94 (37.9%) 1 (2.4%)
3 (strong signal) 48 (19.4%) 0
aSignificantly higher in HCC compared to non-tumor liver when 
comparing scores 2 and 3 combined vs scores 0 and 1 combined (P < 
0.001, Fisher's Exact Test).Molecular Cancer 2008, 7:19 http://www.molecular-cancer.com/content/7/1/19
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Silencing of CDC25B delayed tumor progression in a 
xenograft mode
We next studied the in vivo effects of CDC25B suppression
on tumor growth. Hep40 xenografts were grown in nude
mice, and mice were given intratumoral injections of
siRNA2-CDC25B and RNAiMAX (n = 5) or RNAiMAX
alone (n = 5) every 2 days. All mice in the siRNA2-
CDC25B group had a significantly smaller tumor size
compared with that observed in RNAiMAX group (P <
0.05 from day 7 onwards, P < 0.01 from day 15 onwards)
(Fig. 5).
Discussion
We previously identified CDC25B mRNA to be signifi-
cantly up-regulated in human HCC tumor compared to
non-tumor liver tissues. Herein, we validated the signifi-
cant over-expression of CDC25B transcript in HCC using
quantitative real-time PCR, and of CDC25B protein using
immunohistochemical staining of tissue arrays. Addition-
ally, we found that the specific silencing of CDC25B
expression (by up to 90%) in HCC cell lines inhibited in
vitro cell proliferation, migration, and invasion, and also
delayed HCC xenograft growth in vivo. Our data suggest
that CDC25B, a key factor in regulating the cell cycle, may
be a potential therapeutic target in HCC.
CDC25B is over-expressed in various types of human car-
cinomas, but the mechanism(s) regulating its expression
remains unclear. Previous studies in colorectal [25], gas-
tric [17], non-Hodgkin's [18] and ovarian cancers [22]
showed that CDC25 over-expression was not due to gene
amplification. It was originally shown that the transcrip-
tional and catalytic activities of CDC25B are directly regu-
lated by two other protooncogene products, c-raf and c-
Myc, respectively [26,27]. As CDC25B contains functional
binding sites for Myc/Max [27], many studies have looked
for a correlation between c-Myc and CDC25 expression.
Positive correlation has been detected in non-Hodgkin's
lymphoma [18], neuroblastoma [28], non-small cell lung
cancer [29]. In HBV associated HCC, HBx directly up-reg-
ulates Myc expression and induces hepatocarcinogenesis
[30]. Additionally, chromosomal alterations frequently
occur on chromosomes 1p, 6q, 8q and 13q in HCC, and
encompass the amplification of c-Myc at 8q [31]. Thus,
the over-expression of CDC25B in HCC could be related
to the up-regulation of c-Myc. Alternatively, it has been
suggested that post-translational modification leads to an
enhanced stability of CDC25B [32]. CDC25B is an unsta-
ble protein whose proteasomal degradation is proposed
to be controlled by beta-TrCP, but a splice variant of
CDC25B (CDC25B2) is not degraded during mitosis, as
are the other isoforms. In particular, up-regulation of the
CDC25B2 variant was found in aggressive non-Hodgkin's
lymphomas and in colorectal carcinoma [33,25]. This iso-
form may contribute to CDC25B up-regulation in human
tumors.
As CDC25B promotes cell cycle progression and is over-
expressed in numerous rapidly dividing cancer cells,
CDC25B over-expression is expected to correlate with the
rate of proliferation, consistent with our results that
CDC25B siRNA suppressed proliferation of HCC cells.
This inhibition of proliferation may result from the
observed G2/M phase arrest caused by CDC25B siRNA.
SiRNA2-CDC25B reduces CDC25B expression in Hep3B and Hep40 cells Figure 2
SiRNA2-CDC25B reduces CDC25B expression in Hep3B and Hep40 cells. A) Both CDC25B mRNA and expression 
levels were reduced dose-dependently by siRNA2-CDC25B in Hep3B cells. B) Both CDC25B mRNA and expression levels 
were reduced dose-dependently by siRNA2-CDC25B in HepG2 cells. Cells were transfected with siRNA2-CDC25B at differ-
ent concentrations (1, 12.5, 25, 50 and 100 nM) for 48 hours and RNA extracted for analysis by quantitative real-time PCR as 
described under 'Materials and Methods'. Cell were harvested and lysed and Western blotting was performed as described. 
The level of CDC25B mRNA expression was normalized with that of human 18s RNA expression. The level of CDC25B 
mRNA in the untransfected cells were designated as 100%. Columns, mean of three independent experiments; bars, SD. Cells 
were harvested 48 hours after transfection and cell lysates detected for CDC25B and β-Actin using Western blot.Molecular Cancer 2008, 7:19 http://www.molecular-cancer.com/content/7/1/19
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CDC25B over-expression was found to be significantly
associated with a high proliferative activity of human
non-hodgkin's lymphomas [18], and to enhance the pro-
liferation of mammary epithelial cells in transgenic mice
over-expressing human CDC25B [34]. CDC25B over-
expression in tumors may help to circumvent many of the
checkpoints that would otherwise hinder cell prolifera-
tion, and this lack of proper checkpoint control further
contributes to the malignant nature of many tumors
[35,36]. The correlation between CDC25B and c-Myc
expression levels may also suggest that c-Myc contributes
towards the proliferative activity of tumors with high
CDC25B levels [18,37].
Our functional assays further suggest that CDC25B pro-
motes cellular invasion and migration of HCC cells. Con-
sistently, the over-expression of CDC25B in gastric cancer
was reported to be associated with advanced stage and
deep invasion [17], and also with high rates of lymphatic
invasion and lymph node metastasis [38]. In another
study, CDC25B was more frequently found in patients
with deeper tumor invasion and lymph node metastasis
in squamous cell carcinomas of the esophagus [20].
CDC25B and CDC25C are thought to be regulators of the
G2-M transition through their ability to dephosphorylate
and activate the cdk1/CDC2-cyclin B mitotic kinase com-
plex, which is required for cell entry into mitosis [4]. The
Suppression of CDC25B expression by siRNA2-CDC25B inhibits cell proliferation, migration, and invasion Figure 3
Suppression of CDC25B expression by siRNA2-CDC25B inhibits cell proliferation, migration, and invasion. A) 
The growth rates of siRNA2-CDC25B transfected and control cells were determined using the proliferation assay described 
under 'Materials and Methods'. The data were obtained from three independent experiments, with triplicates in each experi-
ment. B) Invasion and migration of siRNA2-CDC25B transfected and control cells were assessed 48 hours post-transfection, 
using BD Biocoat Matrigel and control chambers respectively. Invaded or migrated cells were stained and counted (per high 
power field, HPF). Columns, mean of three independent experiments; bars, SD; *P < 0.01 for siRNA2-CDC25B versus siRNA-
N transfected cells.Molecular Cancer 2008, 7:19 http://www.molecular-cancer.com/content/7/1/19
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upregulation of Cdc2 has been found to enhance cell
migration, and was correlated with a more motile pheno-
type of cancer cells [39,40]. The ectopic expression of
Cdc2 could increase cell migration via a specific associa-
tion with cyclin B2 and its downstream effector caldes-
mon, which binds to actin [39,40]. This event could lead
to changes in actin filament dynamics and subsequent cell
migration. Additionally, integrin and PFTK1 have been
shown to promote cell invasion and migration through
CDC2 [39,41]. By analogy, we postulate that CDC25B
may function in a similar manner in the modulation of
HCC cell motility.
Conclusion
Taken together, our data provide evidence that CDC25B
may be a potential target for the clinical management of
HCC: it is significantly over-expressed in HCC compared
to non-tumor liver; the specific silencing of CDC25B
expression inhibited HCC cell growth in vitro and in vivo,
and also inhibited HCC cell migration and invasion in
vitro. These observations are consistent with other reports
[23], and further provide rationale for the development of
specific CDC25B small molecule inhibitors as novel
agents for cancer treatment [23,42-47]. However, these
small molecule inhibitors are often not selective due to
considerable structural similarity of the active site regions
of the CDC25 family of proteins. Based on our encourag-
ing data with CDC25B specific siRNA, we propose that
siRNA may offer a new approach to targeting CDC25B
expression and activity in HCC and other malignancies,
leading to inhibitions of tumor cell growth and invasion.
Methods
Cell culture
The human HCC cell lines Hep3B and Hep40 were pur-
chased from ATCC (Manassas, VA). The cells were cul-
tured in Dulbecco's Modified Eagle's Medium (DMEM)
(ATCC, Manassas, VA), supplemented with 10% fetal
bovine serum (FBS) (Invitrogen, Carlsbad, CA), 100 µg/
ml penicillin and 100 µg/ml streptomycin. Cells were
maintained at 37°C in a humidified atmosphere with 5%
CO2.
Cells with reduced CDC25B level are delayed in G2/M transition Figure 4
Cells with reduced CDC25B level are delayed in G2/M transition. Hep3B and Hep40 cells were transfected with 
siRNA2-CDC25B, siRNA-N or RNAiMAX for 48 hours. Cell cycle distribution was determined by flow cytometry. A. Repre-
sentative set of histograms for transfected and control cells. B. Percentage of cells in G2 stage. Columns, mean of at least three 
independent experiments; bars, SD; P < 0.05 for siRNA2-CDC25B versus siRNA-N transfected cells.Molecular Cancer 2008, 7:19 http://www.molecular-cancer.com/content/7/1/19
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Semi-quantitative real-time PCR
Quantification of CDC25B transcript (from both patient
specimens and cell lines) was performed using the
MX3000P Real-Time PCR System (Stratagene, La Jolla,
CA) as previously described [48]. Human CDC25B (Assay
ID: Hs01550934_m1) and 18s rRNA (normalization con-
trol) primers and probe reagents were purchased as Pre-
Developed TaqMan Gene Expression Assay reagents from
Applied Biosystems (Foster City, CA, USA). Transcript
quantification was performed in at least duplicate for
every sample. The amount of CDC25B was normalized
with 18s rRNA to control for RNA amount variation.
Paired (HCC and adjacent non-tumor liver) tissues were
obtained from 24 patients who underwent liver resection
for HCC. This study was approved by the Institutional
Review Board for the use of human subjects in medical
research, and informed consent was obtained from
patients prior to liver resection.
Immunohistochemistry
Immunohistochemistry was performed using DAKO
Envision Plus Kit. (Dako, Carpinteria, CA, USA). Rabbit
polyclonal affinity-purified antipeptide antisera against
CDC25B were generated by Applied Genomics Inc. (Sun-
nyvale, CA, USA). We used four tissue microarrays for this
study, which consisted of archived tissues retrieved from
surgical pathology files. In total, there were 42 normal liv-
ers and 248 malignant hepatocellular carcinomas, among
other control tissues. Tissue arrays were constructed as
previously described [49] with core sizes ranging from 0.6
to 2 mm on different arrays. Arrays were scored using a
four-tier scale: 0 – negative (no staining), 1 – weak signal
(weak staining in < 50% of cells), 2 – intermediate signal
(weak staining in ≥ 50% or strong staining in < 50% of
cells), 3 – strong signal (strong staining in ≥ 50% of cells).
Small interfering RNA transfection
CDC25B-specific siRNAs and Silencer negative control #1
(siRNA-N) were purchased from Ambion, Inc. (Austin,
TX). The sequences for CDC25B-specific siRNAs are:
siRNA1-CDC25B (GCCGGAUCAUUCGAAACGATT),
siRNA2-CDC25B (GGAAAAGGACCUCGUCAUGTT),
siRNA3-CDC25B (GCUCUUACUCUUUCCUAUUTT).
The transfection reagent RNAiMAX (Invitrogen, Carlsbad,
CA) was used to transfect these siRNAs into Hep3B and
Hep40 cells, using the reverse transfection method
according to the manufacturer's instructions.
Western blotting
Transfected cells were harvested and lysed in PARIS lysis
buffer purchased from Ambion, Inc. (Austin, TX). Immu-
noblotting was done with rabbit polyclonal antibody
against CDC25B at 250 fold dilution. (Applied Genomics,
Inc., Burlingame, CA).
Cell proliferation assay
For the assessment of cell growth, Hep3B and Hep40 cells
transfected with 50 nM siRNA2-CDC25B or siRNA-N
were plated on a 96-well plate in triplicate wells. Cell
growth was determined by the CellTiter 96 Aqueous One
Solution Cell Proliferation Assay (Promega, Madison,
Wisconsin, USA) according to the manufacturer's proto-
col. Optical density (OD) was read at 490 nm at various
time points using a SAFIRE microplate reader (TECAN,
Research Triangle Park). Once cells have attached (about
4 hours after transfection), a background OD value was
obtained; the corresponding background values were then
subtracted from data obtained from each well. Three inde-
pendent experiments were done.
Invasion/migration assays
Invasion assays were done using the BD Biocoat Matrigel
chamber in 24-well plates (BD Biosciences Labware, Bed-
ford, MA). Transfected cells were added to coated filters (5
× 104 cells/filter) in 500 µl of serum-free DMEM in tripli-
cate wells. In the lower compartments of the chambers, a
Suppression of CDC25B expression by siRNA2-CDC25B  delayed tumor progression in a xenograft model Figure 5
Suppression of CDC25B expression by siRNA2-
CDC25B delayed tumor progression in a xenograft 
model. Hep40 cells were subcutaneously inoculated into the 
flanks of 10 mice (107 for each). When the tumor size 
reached an average of 200 mm3, 5 mice were given 8 µl 
RNAiMAX diluted to 30 µl with PBS, and another 5 mice 
given 5 µg siRNA and 8 µl RNAiMAX diluted to 30 µl with 
PBS by intratumor injection every two days. The tumor vol-
ume was assessed before each injection using a digital caliper. 
Significant differences in the tumor volumes of both groups 
were observed beginning from day 7 of siRNA2-CDC25B 
injection (P < 0.05). Columns, mean of the tumor size of five 
mice; bars, SD.Molecular Cancer 2008, 7:19 http://www.molecular-cancer.com/content/7/1/19
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volume of 750 µl of chemoattractant (DMEM with 20%
FBS) was added. After 48 hours incubation at 37°C in a
5% CO2 incubator, the non-invading cells on the upper
surface of the filter were wiped off using a cotton swab.
Cells that invaded through the filters were fixed, stained
with Diff-Quik Stain Set (Dade Behring Inc., Newark, DE,
USA), and counted under the microscope by randomly
selecting 6 fields per filter (×100 magnification). The
migration assay was done in a similar manner but without
the Matrigel coating on the filters. Two independent
experiments were done for each assay.
Cell cycle analysis
Cells were transfected with Silencer negative control
siRNA-N and siRNA2-CDC25B and then plated on 12-
well chamber. Two days after transfection, the floating
cells were collected and the adherent cells were detached
by trypsin treatment. The floating and detached cells were
combined, washed twice with PBS containing 1% BSA,
and then were exposed to 70% ethanol at 4°C overnight.
After resuspending in PBS containing 1% BSA, cells were
subsequently digested by RNase in PBS (100 µg/mL) for
30 min on 37°C, and then stained with propidium iodide
(PI) (50 µg/ml in PBS). After incubation for 30 min on ice
in the dark, cells were analyzed by flow cytometry (BD
FACScan). Cell cycle data were analyzed by Flowjo soft-
ware.
Xenograft experiments
All animal experiments were approved by the Administra-
tive Panel on Laboratory Animal Care of Stanford. Ten
nude mice (Athymic nu/nu, Taconic, NY), ages 4 to 6
weeks (about 20 g of weight) were randomly divided into
two groups. Hep40 cells were harvested and mixed with
an equal volume of Matrigel (BD Biosciences, Bedford,
MA). Cells (10 million) were inoculated into the flank of
nude mice. After 50 days, when the average tumor volume
(V) reached 200 mm3 in each group, the mice were given
intratumoral injections of 5 µg siRNA2-CDC25B and
RNAiMAX in 30 µl PBS or RNAiMAX alone in 30 µl PBS
(as control) every two days. Growth curves were plotted
using average tumor volume within each experimental
group at the set time points. The tumor dimensions were
measured before each injection using a digital caliper, and
the tumor volume calculated using the formula: V = π/6 ×
larger diameter × (smaller diameter)2.
Statistical analysis
The statistical analyses were aided by the SPSS version
15.0 software package (SPSS Inc., Chicago, IL, USA). Sta-
tistical significance was determined by one-way ANOVA,
independent-samples T-Test, or Fisher's Exact Test. P val-
ues of less than 0.05 and 0.01 were considered statistically
significant and highly significant, respectively.
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